Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial.
Achim Rittmeyer
No relevant relationships to disclose
Arnaud Scherpereel
Honoraria - Roche
Research Funding - Roche
Vera A. Gorbunova
No relevant relationships to disclose
Radj Gervais
No relevant relationships to disclose
Anders Vikström
Honoraria - Lilly; Roche
Research Funding - Roche
Christos Chouaid
No relevant relationships to disclose
Antonio Chella
No relevant relationships to disclose
Joo-Hang Kim
No relevant relationships to disclose
Myung-Ju Ahn
No relevant relationships to disclose
Martin Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Pfizer; Roche
Antonio Pazzola
No relevant relationships to disclose
Heung Tae Kim
No relevant relationships to disclose
Joachim Aerts
No relevant relationships to disclose
Harry J.M. Groen
Consultant or Advisory Role - Lilly; Pfizer; Roche
Research Funding - Lilly; Roche
Claire Morando
No relevant relationships to disclose
Anderson Loundou
No relevant relationships to disclose
Fabrice Barlesi
Consultant or Advisory Role - Lilly; Roche
Research Funding - Roche